[Pilot study-previously treated advanced non-small cell lung cancer].

This pilot study was performed to evaluate the safety and efficacy of weekly paclitaxel (TXL) administration by 1-hour infusion. A total of 10 patients with previously-treated advanced non-small cell cancer (NSCLC) were treated with weekly paclitaxel. TXL was administered weekly at a dose of 80 mg/m2, 3 times in a 4-week cycle, or 6 times in an 8-week cycle.

Fusion of mature dendritic cells and human T-lymphotropic virus type I infected T cells: its efficiency as an antigen-presenting cell.

Monocyte-derived dendritic cells (DCs) from adult T cell leukemia are impaired in taking up exogenous antigens. To overcome this impairment, we fused unpulsed DCs to human T-lymphotropic virus type I (HTLV-I)-infected CD4(+) T cells (fusion DC-T cells). The efficiency of fusion was 50% and the fusion cells expressed higher HLA-ABC and CD86 Ags than HTLV-I-infected DCs.